Expert Opinion On Therapeutic Targets

雜志介紹

Expert Opinion On Therapeutic Targets雜志介紹

《Expert Opinion On Therapeutic Targets》是一本以English為主的未開放獲取國際優秀期刊，中文名稱治療靶點專家意見，本刊主要出版、報道醫學-PHARMACOLOGY & PHARMACY領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCIE收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為4.6，最新CiteScore 指數為8.9。

本刊近期中國學者發表的論文主要有：

• Targeting endoplasmic reticulum stress-the responder to lipotoxicity and modulator of non-alcoholic fatty liver diseases

  Author: Luo, Yu; Jiao, Qiangqiang; Chen, Yuping

• The participation of non-canonical autophagic proteins in the autophagy process and their potential as therapeutic targets

  Author: Yin, Yiming; Zhou, Yourong; Yang, Xiaochun; Xu, Zhifei; Yang, Bo; Luo, Peihua; Yan, Hao; He, Qiaojun

• Novel therapeutic perspectives for crescentic glomerulonephritis through targeting parietal epithelial cell activation and proliferation

  Author: Huang, Yanjie; Zhao, Xueru; Zhang, Qiushuang; Yang, Xiaoqing; Hou, Gailing; Peng, Chaoqun; Jia, Mengzhen; Zhou, Li; Yamamoto, Tatsuo; Zheng, Jian

• Recent advances of Phosphodiesterase 4B in cancer

  Author: Miao, Yu; Peng, Li; Chen, Zhaolin; Hu, Ying; Tao, Liangsong; Yao, Yan; Wu, Yincui; Yang, Dashuai; Xu, Tao

英文介紹

Expert Opinion On Therapeutic Targets雜志英文介紹

The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials.

The Editors welcome:

Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development.

Articles should not include clinical information including specific drugs and clinical trials.

Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs.

The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.